On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to 2 billion doses of our COVID-19 vaccine for 2021. This new BioNTech site will become one of the largest mRNA manufacturing sites in Europe with an annual production capacity of up to 750 million doses of COVID-19 vaccine, once fully operational. BioNTech plans to be able to produce up to 250 million doses of BNT162b2 in the first half of 2021.